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2. Measurement of absolute myocardial blood flow and myocardial blood flow reserve (MBFR) 3. Measurement of regional and global myocardial systolic function at peak-stress (rather than poststress as is done with SPECT MPI) 2 4. Efficient (30 minute) rest-stress imaging protocol 5. Robust attenuation and scatter correction with superior diagnostic accuracy. 3 The low radiation exposure is a result of the very short (76 second) half-life of 82 Rb. Radiation exposure for laboratory personnel is also extremely low for 82 Rb PET MPI as the entire protocol is performed in the PET camera, and the stress laboratory personnel and nuclear technologists can monitor the procedure from a shielded control room. There is negligible residual radioactivity present after the 82 Rb study, which eliminates the radiation exposure to other medical personnel who are in close proximity to the patient (e.g., a sonographer who performs a transthoracic echocardiogram immediately following the PET MPI study).
The short half-life of 82 Rb also facilitates a rapid rest-stress imaging protocol. Equivalent 82 Rb doses can be administered for rest and peak-stress images (ensuring high quality for both sets of images), without the need to delay the peak-stress 82 Rb infusion or increase the peak-stress dose to compensate for residual resting tracer activity.
DISADVANTAGES OF 82 RB AS A PET PERFUSION TRACER
However, the short half-life of 82 Rb poses challenges as well.
1.
82 Rb PET MPI is only feasible with pharmacologic stress, as there is rapid decay of 82 Rb activity and insufficient time to transfer the patient from a treadmill to the PET camera for post-exercise image acquisition. 2. The rapid decay of 82 Rb makes it impossible to repeat image acquisition in the event of patient motion. If severe patient motion artifact occurs on a peak-stress 82 Rb image, it is necessary to repeat the pharmacologic stress infusion as well as the 82 Rb infusion.
There are other limitations to the use of 82 Rb as a perfusion tracer for PET MPI. thallium, a SPECT perfusion tracer with favorable myocardial uptake properties), the myocardial extraction fraction of 82 Rb has been reported to be lower than that of other PET perfusion tracers. 4 The lower myocardial extraction fraction leads to an earlier plateau in myocardial tracer uptake during vasodilator stress and an underestimation of the blood flow disparity between normally perfused and hypoperfused myocardial regions. The clinical implication is an underestimation of the extent and severity of CAD by 82 Rb PET MPI. 3. The positrons produced by decay of 82 Rb are higher in energy than the positrons produced by other PET radionuclides, resulting in a longer positron range (the average distance traveled by a positron before interacting with an electron). 5 The impact of the longer positron range of 82 Rb is poorer spatial resolution of 82 Rb PET images compared to images obtained using radionuclides with a shorter positron range (e.g., 13 There are a few considerations regarding the applicability of the present study to patients referred for clinically indicated PET MPI.
1. The study population was small (12 subjects), predominantly male (10 of 12 subjects), normal body weight (BMI 20-29), healthy, and taking no medications. This patient population is very different from the population of patients referred for clinically indicated PET MPI. While it is understandable that young healthy volunteers are convenient subjects for a demanding and time-consuming phase 1 study, the potential impact of this healthy young study population (i.e., lower risk for adverse events) needs to be considered. 2. The study was limited to exercise and adenosine stress, and therefore, the biodistribution and radiation dosimetry results cannot be directly extrapolated to dipyridamole stress, regadenoson stress, dobutamine stress, or any of the vasodilator stress agents combined with low-level treadmill exercise. 3. The study was performed using 2D (with collimation) rather than 3D (without collimation) PET MPI. There is potential for using lower 18 F flurpiridaz tracer doses with a 3D imaging protocol. 4. The authors were not able to provide information regarding the radiation exposure to laboratory personnel with 18 F flurpiridaz compared to 82 Rb. Given the long half-life of 18 F, there will be potential for higher radiation exposure to laboratory personnel and other medical staff in the facility. This concern needs to be addressed, and potential solutions to minimize exposure to medical staff should be explored (e.g., shielded waiting rooms might be needed for patients undergoing 18 F flurpiridaz PET MPI, and 3D PET imaging protocols should be developed to reduce 18 F flurpiridaz dosing).
In the end, the feasibility of exercise stress may not emerge as an important clinical advantage of 18 F flurpiridaz, as measurement of peak-exercise myocardial blood flow (and MBFR) would be technically challenging and would likely require alternative blood flow quantitative methods that do not depend on initiation of imaging prior to appearance of the tracer. 10 The PET MPI imaging protocols for 18 F flurpiridaz will likely be less efficient than the protocols for 82 Rb, with proposed delays of 60 minutes and 30 minutes between the resting and peak-stress images for exercise and adenosine stress, respectively. 9 Therefore, a rest-stress 18 F flurpiridaz protocol duration will undoubtedly exceed the duration of a rest-stress 82 Rb PET MPI protocol. When considering the advantages and disadvantages of 82 Rb and 18 F flurpiridaz as tracers for PET MPI, there are many factors to consider, including protocol efficiency, radiation exposure to patients and laboratory personnel, diagnostic capabilities, protocol flexibility, and cost of the tracer. Will 18 F flurpiridaz replace 82 rubidium as the most commonly used perfusion tracer for PET MPI? Only time will tell.
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